University of Wisconsin Carbone Cancer Ctr

Madison, Wisconsin 53792

1 studies enrolling now · 2 studies all time

What they study most

ALK Gene Rearrangement Positive, Advanced Solid Tumors, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer

Studies at this site

• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer — Completed
• Expanded Access to Ensartinib for Participants With ALK+ NSCLC — Available (expanded access)